ArticleActa neurologica Belgica2026
Correlation of serum glial fibrillary acidic protein (GFAP) and soluble triggering receptor expressed on myeloid cells-2 (sTREM-2) levels with disability and clinical characteristics in multiple sclerosis.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Astrocytes in Multiple Sclerosis: Getting to the Core.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSerum biomarkers such as soluble triggering receptor expressed on myeloid cells-2 (sTREM-2) and glial fibrillary acidic protein (GFAP) can indicate astrocyte and microglial activity in Multiple sclerosis (MS) patients. GFAP has been linked to disability progression, but the role of serum sTREM-2 in MS disability remains unclear. OBJECTIVES/
aimsTo assess the relationship between serum levels of GFAP and sTREM-2, the Expanded Disability Status Scale (EDSS), and clinical characteristics in MS patients.
methodsThis cross-sectional study involved 120 MS patients who were diagnosed using the updated 2017 McDonald criteria at Sina Hospital in Tehran, Iran. Following the collection of demographic data and EDSS scores, patient blood samples were obtained, and serum levels of GFAP and sTREM-2 were measured using the enzyme-linked immunosorbent assay (ELISA) method. After determining normality, the connection between serum GFAP and sTREM-2 levels and clinical variables was examined using appropriate tests. The squared correlation coefficient was calculated for significant biomarker-EDSS correlations to estimate the percentage of explained/shared variance. The significance level was set at p < 0.05.
resultsThe mean ± standard deviation (SD) age of participants was 38.72 ± 8.86 years. The majority were female, comprising 79.2% of the sample (95 out of 120). Most patients had relapsing-remitting MS (RRMS, 79.2%). The median EDSS score was 2.50 (IQR 1.0-4.0). The median serum levels of GFAP and sTREM-2 were 1.13 (0.85-1.38) ng/mL and 0.60 (0.39-0.86) ng/mL, respectively. Both GFAP and sTREM-2 showed statistically significant but modest-to-weak positive correlations with EDSS. GFAP was correlated with EDSS (r = 0.279, p = 0.002), corresponding to approximately 7.8% explained/shared variance, while sTREM-2 was correlated with EDSS (r = 0.199, p = 0.030), corresponding to approximately 4.0% explained/shared variance. In multivariable linear regression models adjusting for age, sex, disease duration, MS subtype, DMT efficacy, and relapse rate, both GFAP (p = 0.020) and sTREM-2 (p = 0.035) remained independently associated with EDSS. There was no significant correlation found between age, disease duration, annual relapse rate, MS subtypes, treatment groups, and the biomarkers studied.
conclusionOur results show statistically significant but modest-to-weak positive correlations between EDSS and serum levels of sTREM-2 and GFAP, suggesting these biomarkers could help evaluate current disability and further our knowledge of MS pathophysiology.
Indexed as
Identifiers
42310253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.